Cure8 research brief
The article provides up-to-6-year safety data for ontamalimab in people with moderate-to-severe UC and CD, which helps patients and clinicians understand long-term tolerability of this investigational anti–MAdCAM-1 therapy.
Because ontamalimab’s Phase 3 program was later terminated, these safety data are mostly useful for historical context and for researchers tracking safety of therapies targeting gut-homing pathways.
Patients with IBD interested in biologic treatment safety, clinicians who manage long-term therapy for UC/CD, and researchers studying anti–MAdCAM-1 approaches or long-term safety of investigational IBD drugs.
This open-label long-term safety extension enrolled patients who had completed earlier phase 3 induction and maintenance trials of ontamalimab and followed them for up to 6 years while receiving 25 mg or 75 mg every 4 weeks. The report focuses on adverse events, serious adverse events, and deaths; efficacy was not formally evaluated in this extension.
Most participants experienced at least one adverse event; a smaller proportion had serious adverse events, and a few deaths occurred that the authors state were not related to ontamalimab.
The study includes both ulcerative colitis and Crohn’s disease cohorts but many more UC than CD patients were enrolled, which affects how broadly the safety findings apply to CD. Because the original Phase 3 program was terminated in 2020, ontamalimab is not an approved therapy and the clinical-development context matters when interpreting these results.
Structured content depth: abstract — the brief is grounded in the article abstract supplied. The extension study was open-label and focused on safety; efficacy was not formally evaluated. The Phase 3 development program for ontamalimab was terminated in 2020, so the drug is not an approved treatment.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
